A. Scott Pierson

1.1k total citations
8 papers, 412 citations indexed

About

A. Scott Pierson is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, A. Scott Pierson has authored 8 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 1 paper in Organic Chemistry. Recurrent topics in A. Scott Pierson's work include Cancer Treatment and Pharmacology (4 papers), Cancer therapeutics and mechanisms (3 papers) and Angiogenesis and VEGF in Cancer (2 papers). A. Scott Pierson is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Cancer therapeutics and mechanisms (3 papers) and Angiogenesis and VEGF in Cancer (2 papers). A. Scott Pierson collaborates with scholars based in United States. A. Scott Pierson's co-authors include Daniel L. Gustafson, Joseph A. Zirrolli, Rajesh Agarwal, Gail S. Harrison, Thomas W. Flaig, Lih‐Jen Su, L. Michael Glodé, Frances Crighton, Scott N. Holden and Sabine Eckhardt and has published in prestigious journals such as Clinical Cancer Research, Annals of Oncology and Cancer Chemotherapy and Pharmacology.

In The Last Decade

A. Scott Pierson

8 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Scott Pierson United States	8	227	199	107	103	83	8	412
Radka Václavíková Czechia	15	342 1.5×	103 0.5×	204 1.9×	42 0.4×	79 1.0×	36	608
Pablo Cano Canada	9	127 0.6×	114 0.6×	283 2.6×	66 0.6×	130 1.6×	12	544
Yu‐Hsuan Lan Taiwan	14	251 1.1×	126 0.6×	94 0.9×	28 0.3×	43 0.5×	37	495
Tung‐Kwang Lee United States	13	248 1.1×	77 0.4×	85 0.8×	25 0.2×	65 0.8×	15	478
Weili Min China	17	299 1.3×	92 0.5×	132 1.2×	98 1.0×	37 0.4×	26	591
Xiwei Ji China	9	229 1.0×	48 0.2×	129 1.2×	64 0.6×	27 0.3×	21	459
Xiaonan Xi China	11	279 1.2×	54 0.3×	79 0.7×	93 0.9×	50 0.6×	15	501
Zhonghuang Li China	15	288 1.3×	67 0.3×	101 0.9×	33 0.3×	42 0.5×	32	508
Xiaodan Sun China	14	304 1.3×	62 0.3×	113 1.1×	56 0.5×	36 0.4×	39	556

Countries citing papers authored by A. Scott Pierson

Since Specialization

Citations

This map shows the geographic impact of A. Scott Pierson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Scott Pierson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Scott Pierson more than expected).

Fields of papers citing papers by A. Scott Pierson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Scott Pierson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Scott Pierson. The network helps show where A. Scott Pierson may publish in the future.

Co-authorship network of co-authors of A. Scott Pierson

This figure shows the co-authorship network connecting the top 25 collaborators of A. Scott Pierson. A scholar is included among the top collaborators of A. Scott Pierson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Scott Pierson. A. Scott Pierson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Lieu, Christopher H., Laura Q.M. Chow, A. Scott Pierson, et al.. (2008). A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Investigational New Drugs. 27(1). 53–62. 7 indexed citations

2.

Gore, Lia, et al.. (2006). A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Annals of Oncology. 17(11). 1709–1717. 13 indexed citations

3.

Flaig, Thomas W., Daniel L. Gustafson, Lih‐Jen Su, et al.. (2006). A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs. 25(2). 139–146. 264 indexed citations

4.

Witta, Samir E., Daniel L. Gustafson, A. Scott Pierson, et al.. (2004). A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors. Clinical Cancer Research. 10(21). 7229–7237. 22 indexed citations

5.

Gustafson, Daniel L., Michael E. Long, Joseph A. Zirrolli, et al.. (2003). Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemotherapy and Pharmacology. 52(2). 159–166. 50 indexed citations

6.

Herbst, Roy S., et al.. (2002). Angiogenesis inhibitors in clinical development for lung cancer. Seminars in Oncology. 29(1). 66–77. 37 indexed citations

7.

Pierson, A. Scott, Peter Gibbs, Jon Richards, et al.. (2002). A Phase II Study of Irofulven (MGI 114) in Patients with Stage IV Melanoma. Investigational New Drugs. 20(3). 357–362. 11 indexed citations

8.

Hidalgo, Manuel, et al.. (2001). Therapeutic angiogenesis inhibitors in the treatment of cancer.. PubMed. 47. 159–90. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact